Poehling Capital Management INC. Lowers Stock Position in Organon & Co. $OGN

Poehling Capital Management INC. lowered its position in shares of Organon & Co. (NYSE:OGN) by 36.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 201,459 shares of the company’s stock after selling 114,090 shares during the quarter. Poehling Capital Management INC.’s holdings in Organon & Co. were worth $1,950,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Organon & Co. by 22.4% in the 2nd quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock valued at $55,000 after purchasing an additional 1,034 shares during the period. Maryland State Retirement & Pension System grew its holdings in Organon & Co. by 1.4% during the second quarter. Maryland State Retirement & Pension System now owns 88,420 shares of the company’s stock valued at $856,000 after purchasing an additional 1,195 shares during the period. Allworth Financial LP grew its stake in shares of Organon & Co. by 65.9% during the 2nd quarter. Allworth Financial LP now owns 4,501 shares of the company’s stock worth $44,000 after acquiring an additional 1,788 shares during the period. Yousif Capital Management LLC raised its stake in Organon & Co. by 2.3% in the 2nd quarter. Yousif Capital Management LLC now owns 79,975 shares of the company’s stock valued at $774,000 after acquiring an additional 1,789 shares during the period. Finally, Xponance Inc. boosted its holdings in Organon & Co. by 15.2% in the 1st quarter. Xponance Inc. now owns 13,828 shares of the company’s stock worth $206,000 after buying an additional 1,823 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OGN has been the topic of a number of recent research reports. Piper Sandler cut Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective on the stock. in a report on Monday, October 27th. Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. Morgan Stanley decreased their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Organon & Co. presently has a consensus rating of “Hold” and an average target price of $12.50.

Organon & Co. Stock Performance

NYSE:OGN opened at $7.55 on Monday. Organon & Co. has a twelve month low of $6.18 and a twelve month high of $17.23. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The firm’s fifty day simple moving average is $9.19 and its 200 day simple moving average is $9.37. The stock has a market cap of $1.96 billion, a P/E ratio of 3.93, a price-to-earnings-growth ratio of 1.61 and a beta of 0.59.

Organon & Co. (NYSE:OGN) last released its earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the business posted $1.38 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, research analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Thursday, November 20th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 20th. Organon & Co.’s dividend payout ratio (DPR) is 4.17%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.